Skip to content
OpenCapital
Get started

Palvella Therapeutics PVLA Cash & Equivalents

Other financials

Income statement

See full
Revenue$53.0K-97.3%
Operating income-$14.9M-88.7%
Net income-$15.8M-92.6%
EPS (diluted)-$1.20-62.2%

Balance sheet

See full
Total debt$584.0K—
Total equity$232.3M+318%
Total assets$263.8M+232%

Cash flow

See full
Operating cash flow-$10.9M-60.5%
CapEx--100%
Free cash flow-$2.7M+72.0%

Valuation

See full
Market cap$1.7B+468%
Enterprise value$1.5B—
P/S41.6×—

Profitability

See full
Operating margin-183.2%-13.5pp
Net margin71.7%+40.4pp
FCF margin-99.8%-34.2pp

Returns & leverage

See full
Return on equity-34.2%—
Debt / equity0×—
Current ratio28.9×+20.0×

Ask your AI about Palvella Therapeutics's cash & equivalents.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Palvella Therapeutics's cash & equivalents?
Palvella Therapeutics (PVLA) reported cash & equivalents of $206.39M in Q1 2026.
How has Palvella Therapeutics's cash & equivalents changed year-over-year?
Palvella Therapeutics's cash & equivalents increased by 172.9% year-over-year, from $75.63M to $206.39M.
What is the long-term trend for Palvella Therapeutics's cash & equivalents?
Over 5 years (2020 to 2025), Palvella Therapeutics's cash & equivalents has grown at a -3.8% compound annual growth rate (CAGR), from $70.44M to $57.98M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.